

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5269907

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Nicolas Guisot	07/11/2018
RECEIVING PARTY DATA	
Name:	REDX PHARMA PLC
Street Address:	BLOCK 33F, MERESIDE, ALDERLEY PARK, ALDERLEY EDGE
City:	CHESHIRE
State/Country:	UNITED KINGDOM
Postal Code:	SK10 4TG
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15762367
CORRESPONDENCE DATA	
Fax Number:	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	+1 (612) 638-5719
Email:	apsi@fr.com
Correspondent Name:	ALYSHA A. DICKE
Address Line 1:	FISH & RICHARDSON P.C.
Address Line 2:	P.O.BOX 1022
Address Line 4:	MINNEAPOLIS, MINNESOTA 55440-1022
ATTORNEY DOCKET NUMBER:	42001-0043US1
NAME OF SUBMITTER:	JILL A. WRIGHT
SIGNATURE:	/Jill A. Wright/
DATE SIGNED:	12/06/2018
Total Attachments: 2	
source=EXECUTED ASSIGNMENT#page1.tif	
source=EXECUTED ASSIGNMENT#page2.tif	

ASSIGNMENT

For valuable consideration, the receipt of which I acknowledge, and intending to be bound legally, I, NICOLAS GUISOT, confirm any prior assignment to REDX Pharma PLC, a corporation formed under the laws of United Kingdom and having a principal place of business at Block 33F, Mereside, Alderley Park, Alderley Edge, Cheshire SK10 4TG, United Kingdom, and its successors, transferees, and assignees (collectively the "Assignee"), all of my right, title, and interest throughout the world in the invention(s) (the "Subject Matter") described in patent applications that name me as inventor, are titled "PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER", and were filed on September 16, 2016, as International Application No. PCT/GB2016/052897, GB Application No. 1613947.9 filed August 15, 2016, GB Application No. 1522246.6, filed December 16, 2015 and GB Application No. 1516445.2, filed September 16, 2015 (the "Applications").


This Assignment assigns, to the extent not previously assigned, in addition to the Subject Matter described in the Applications, any right, title, and interest that I own in (a) the Application and all other applications that may be made for, and all patents, utility models, design registrations, and other rights of exclusion and inventors' certificates for, any of the Subject Matter (collectively the "Applications and Granted Rights") in every country or region and under every treaty or convention, (b) the right to claim priority based on and the benefit of the filing date of any of the Applications and Granted Rights under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other applicable treaties or conventions, and (c) the right to pursue, collect, and retain in the Assignee's name or otherwise, damages and any other remedies arising from any past, present, or future infringement of the Subject Matter, the Applications and Granted Rights, and any other rights assigned by this Assignment.

I authorize the Assignee to apply for and pursue protection for any or all of the Subject Matter, the Applications and Granted Rights, and any other rights assigned by this Assignment in all countries, regions, and territories of the world, in my name or in the Assignee's name.

I will communicate to the Assignee (or, at the request of the Assignee to other parties) all known facts in any form relating to the Subject Matter; will execute and provide all oaths and declarations, statements, testimony, assignments, powers of attorney, applications, and


documents; and will perform all other lawful acts necessary or desirable to secure fully to the Assignee the rights, titles, and interests assigned by this Assignment.

I confirm that I was obligated to make this Assignment to my employer at the time of the filing of the Applications due, at least in part, to my employment at RedX Pharma PLC. at the time that the inventions were made.


Nicolas Guisot


Date: 11 July 2018

Witnessed by:

Signature: 

Date: 11 July 2018

Print Name: ARLENE THOMAS


Signature: 

Date: 11 JULY 2018

Print Name: AILEEN THOMASON

The Assignee hereby acknowledges and accepts the foregoing assignment.

Assignee: REDX Pharma PLC

Signature: 

Date: 11 July 2018

Name: Ms Lisa ANSON

Title: CEO, Redx Pharma plc.